Published by the group from National Cancer Center, Korea, this study reported clinical outcomes of 47 patients with intrahepatic cholangiocarcinoma (IHCC) treated with PBT to a total mean dose 63.3 GyE (range: 45-80 GyE) in 10 fractions. With a mean follow-up time 18.3 months, this study reported 2-year freedom from local progression (FFLP), PFS, OS rates, and median time of OS were 86.9%, 16.8%, 42.7% and 21.9 months, respectively; grade ≥ 3 adverse events were observed in four (8.5%) patients. Longer OS of 33.8 months was recorded for patients with localized disease (no viable tumors outside of the PBT sites). These findings suggest that hypofractionated PBT is safe and could offer a high rate of FFLP and promising OS in patients with inoperable or recurrent IHCC.